Komori
Disclosure4559ZERIA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Change to Shareholder Benefit Product Course Contents

The F course for shareholders holding 1,000 shares or more will be changed from the existing two-item set of serum and cream to a two-jar set of medicated beauty cream. The revised course will apply from the allocation based on the record date at the end of March 2026.

Worth reading
60In focus
Scored from 5 of 6 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Decision and Details

Change to the contents of the F course for shareholders holding 1,000 shares or more

Decision27 March 2026 (disclosure date; no resolution date is stated)
Period CoveredThe F course relating to the shareholder benefit program’s twice-yearly allocation record dates, at the end of March and the end of September
ImplementationTo be implemented from the record date at the end of March 2026
Going forwardThe revised F course will be implemented from the record date at the end of March 2026
Quantity / scaleEligible shareholders: holders of 1,000 shares or more; revised product: IONA R Double Action Cream, 30g × 2; previous products: IONA R Whitening Essence, 30mL × 1, and IONA R Wrinkle Concentrate, 15g × 1
Reason

The shareholder benefit program is operated as a token of appreciation for shareholders’ continued support and cooperation

Decision and Details
ItemDetails
Matter CoveredChange to the contents of the F course for shareholders holding 1,000 shares or more
Decision Date27 March 2026 (disclosure date; no resolution date is stated)
Implementation DateTo be implemented from the record date at the end of March 2026
Period CoveredThe F course relating to the shareholder benefit program’s twice-yearly allocation record dates, at the end of March and the end of September
Quantity / scaleEligible shareholders: holders of 1,000 shares or more; revised product: IONA R Double Action Cream, 30g × 2; previous products: IONA R Whitening Essence, 30mL × 1, and IONA R Wrinkle Concentrate, 15g × 1
ReasonThe shareholder benefit program is operated as a token of appreciation for shareholders’ continued support and cooperation
Future plansThe revised F course will be implemented from the record date at the end of March 2026
Items this document does not state (5)
Decision-Making BodyAmountImpact on Business PerformanceGoverning RuleRelated previous disclosures

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explains that it operates the shareholder benefit program as a token of appreciation for shareholders’ continued support and cooperation. No reason is stated for the change to the F course itself.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Change to Shareholder Benefit Product Course Contents | ZERIA PHARMACEUTICAL CO.,LTD. (4559) timely disclosure | Komori